Tower Research Capital (TRC)’s Kailera Therapeutics KLRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$42.7K Buy
3,742
+453
+14% +$7.66K ﹤0.01% 3317
2026
Q2
$72.5K Buy
+3,289
New +$72.3K ﹤0.01% 2447

Other funds holding KLRA

Tower Research Capital (TRC)'s KLRA Position: Q3 2026 in Review

Tower Research Capital (TRC) increased its Kailera Therapeutics (KLRA) stake by 14% in Q3 2026, buying an estimated $7.66K and bringing the position to 3,742 shares worth $42.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3317.

Tower Research Capital (TRC) first reported a position in KLRA in Q2 2026 and has held it in 2 quarters since. The position peaked at $72.5K in Q2 2026. 132 funds tracked by Wall St. Rank hold KLRA as of Q3 2026.

  • Tower Research Capital (TRC) held 3,742 shares of Kailera Therapeutics worth $42.7K as of Q3 2026.
  • Tower Research Capital (TRC) bought 453 Kailera Therapeutics shares in Q3 2026, an estimated $7.66K.
  • Kailera Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #3317 holding.
  • Tower Research Capital (TRC) first reported a position in Kailera Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Tower Research Capital (TRC)'s Kailera Therapeutics position peaked at $72.5K in Q2 2026.
  • 132 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.